Current Report Filing (8-k)
February 24 2020 - 4:59PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2020
ContraFect Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36577
|
|
39-2072586
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
28 Wells Avenue, 3rd Floor, Yonkers, New York 10701
(Address of principal executive offices) (Zip Code)
(914) 207-2300
Registrants telephone number, including area code
N/A
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock,
$0.0001 par value per share
|
|
CFRX
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 8.01 Other Events.
On February 24, 2020, ContraFect Corporation (the Company) issued a press release announcing that the U.S. Food and Drug Administration (FDA)
has granted Breakthrough Therapy designation for exebacase for the treatment of MRSA bacteremia, including right-sided endocarditis, when used in addition to
standard-of-care anti-staphylococcal antibiotics in adult patients.The full text of the press release issued in connection with this announcement is filed as Exhibit
99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CONTRAFECT CORPORATION
|
|
|
|
|
Date: February 24, 2020
|
|
|
|
By:
|
|
/s/ Natalie Bogdanos
|
|
|
|
|
|
|
Natalie Bogdanos
|
|
|
|
|
|
|
General Counsel and Corporate Secretary
|
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024